Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CFD | P00746 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | TOP1 | P11387 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | TNFSF11 | O14788 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.38 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.38 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2912166 | 0.81 | POLB (0.56) | POLBHTTCYP3A4CFDKDM4E | |
| SCHEMBL6901292 | 0.76 | SMN1; SMN2 (0.48) | POLBHTTCYP3A4KDM4ETDP1 | |
| SCHEMBL7566198 | 0.76 | POLB (0.54) | POLBHTTCYP3A4KDM4ETOP1 | |
| SCHEMBL10516942 | 0.75 | HTT (0.68) | HTTCYP3A4CFDKDM4ETOP1 | |
| SCHEMBL8377613 | 0.75 | POLB (0.49) | POLBHTTCFDKDM4ETOP1 | |
| SCHEMBL4466762 | 0.74 | MEN1 (0.52) | POLBHTTCYP3A4KDM4ETDP1 | |
| SCHEMBL23535311 | 0.74 | KDM4E (0.62) | POLBHTTCFDKDM4ETDP1 | |
| SCHEMBL10336107 | 0.73 | KDM4E (0.53) | POLBHTTCFDKDM4ETOP1 | |
| Acetic Acid SCHEMBL7567667 | 0.73 | POLB (0.51) | POLBHTTCYP3A4CFDKDM4E | |
| SCHEMBL7039810 | 0.71 | TNFSF11 (0.51) | POLBCYP3A4TDP1MAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7576094-B2 | Spiro derivatives as lipoxygenase inhibitors | ELI LILLY AND COMPANY (US) | 2009-08-18 | — | — | US | disclosed |
| EP-1836183-A2 | SPIRO DERIVATIVES AS LIPOXYGENASE INHIBITORS | Galileo Pharmaceuticals, Inc. (US) | 2007-09-26 | — | — | EP | disclosed |
| US-7078541-B2 | Benzofuran derivatives | GALILEO PHARMACEUTICALS, INC. (US) | 2006-07-18 | — | — | US | disclosed |
| WO-2006065686-A2 | SPIRO DERIVATIVES AS LIPOXYGENASE INHIBITORS | GALILEO PHARMACEUTICALS, INC. (US) | 2006-06-22 | — | — | WO | disclosed |
| US-20060128790-A1 | Spiro derivatives as lipoxygenase inhibitors | GALILEO PHARMACEUTICALS, INC. | 2006-06-15 | — | — | US | disclosed |
| CN-1252031-C | Method for preparing monoacylated hydroquinone compound | BASF AG (DE) | 2006-04-19 | — | — | CN | disclosed |
| WO-2005027900-A1 | BENZOFURAN DERIVATIVES | GALILEO PHARMACEUTICALS, INC. (US) | 2005-03-31 | — | — | WO | disclosed |
| US-20040063975-A1 | Benzofuran derivatives | EDISON PHARMACEUTICALS, INC. | 2004-04-01 | — | — | US | disclosed |
| EP-1094056-B1 | Process for the preparation of monoacetylated hydrochinone compounds | BASF AG (DE) | 2004-02-25 | — | — | EP | disclosed |
| US-6653346-B1 | Amtiischemic and antiinflammatory agents | GALILEO PHARMACEUTICALS, INC. | 2003-11-25 | — | — | US | disclosed |
| US-6476253-B1 | Process for preparing monoacetylated hydroquinone compounds | BASF AKTIENGESELLSCHAFT (DE) | 2002-11-05 | — | — | US | disclosed |
| CN-1294116-A | Method for preparing monoacylated hydroquinone compound | BASF AG (DE) | 2001-05-09 | — | — | CN | disclosed |
| EP-1094056-A1 | Process for the preparation of monoacetylated hydrochinone compounds | BASF AKTIENGESELLSCHAFT (DE) | 2001-04-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063975-A1 | Benzofuran derivatives | NDUFAB1, AIFM1, NDUFAF1 | POLB 1299/4885HTT 400/4885CYP3A4 823/4885 |
| US-20060128790-A1 | Spiro derivatives as lipoxygenase inhibitors | ALOX15B, ALOX5, ALOX15 | POLB 2855/4885HTT 3071/4885CYP3A4 317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.